Unichem Laboratories Limited NSE:UNICHEMLAB

Unichem Laboratories : Unaudited Results (Consolidated and Standalone) Quarter year ended September 30, 2025

Published November 11, 2025 at 8:27 a.m. UTC

Source: MarketScreener

11th November 2025

Department of Corporate Services BSE Limited,

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

Script Code: 506690

National Stock Exchange of India, Exchange Plaza,

Bandra Kurla Complex,

Bandra (East), Mumbai - 400 051

Symbol: UNICHEMLAB

Dear Sir/Madam, Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors at its Meeting held today, i.e. Tuesday, 11th November 2025 approved Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2025.

Enclosed herewith are the Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2025 along with Limited Review report by Auditors.

The Board meeting commenced at 11:00 a.m. and concluded at 01:00 p.m. The same will also be made available on the Company's website https://www.unichemlabs.com as well as on https://www.bseindia.com and https://www.nseindia.com.

Kindly take the same on your records. Thanking you,

FOR UNICHEM LABORATORIES LIMITED

Pradeep Gautam Bhandari

Date: 2025.11.11

13:01:48 +05'30'

PRADEEP BHANDARI

Head - Legal & Company Secretary

Encl.: a/a

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: https://www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2025

' Crores

Particulars

Quarter ended

Half year ended

Year ended

30.09.2025

30.06.2025

30.09.2024

30.09.2025

30.09.2024

31.03.2025

Unaudited

Unaudited (refer note 6)

Unaudited

Unaudited (refer note 6)

Audited

I Revenue from operations

578.96

526.60

507.36

1,105.56

990.70

2,110.97

11 Other income

20.97

6.82

8.69

27.79

12.45

35.32

Ill Total income (I+II)

599.93

533.42

516.05

1,133.35

1,003.15

2,146.29

IV EXPENSES

Cost of materials consumed

193.06

217.48

201.33

410.54

437.88

888.24

Purchase of stock-in-trade

39.76

51.01

55.28

90.77

78.87

175.78

Changes in inventories of stock-in-trade, finished goods and workin-progress

37.56

(23.44)

(41.81)

14.12

(109.17)

(200.35)

Employee benefits expense

100.13

107.42

101.86

207.55

204.00

402.21

Finance costs

8.24

6.54

4.79

14.78

8.82

21.03

Depreciation and amortization expenses

31.47

31.79

32.26

63.26

64.33

124.56

Other expenses

142.27

151.64

135.21

293.91

283.48

580.23

Total expenses (IV)

552.49

542.44

488.92

1,094.93

968.21

1,991.70

V Share of profit / (loss) in associate (net of tax)

Profit / (Loss) before exceptional items and tax (III- IV+Vj

47.44

(9.02)

27.13

38.42

34.94

154.59

VII Exceptional items - expenses/(income) (Refer note 5)

58.26

VIII Profit / (Loss) before tax (VI-VII)

(10.82)

(9.02)

27.13

(19.84)

34.94

154.59

IX Tax expense

(1) Current tax

0.98

0.96

0.01

1.94

1.42

18.39

(2) Deferred tax charge / (credit) (Refer note 4)

0.09

0.05

2.49

0.14

6.82

(1.20)

(3) Short / (excess) provision for tax (earlier years)

0.44

(0.12)

1.07

1.45

2.50

2.52

8.24

17.07

X Profit / (Loss) for the period after tax (VIII-IX)

(11.89)

(10.47)

24.63

(22.36)

26.70

137.52

XI Other Comprehensive Income / (Loss)

(i) Items that will not be reclassified subsequently to profit or loss

- Remeasurement of the net defined benefit plan

(ii) Income tax (expense) / credit relating to items that will not

be reclassified to profit or loss

- Remeasurement of the net defined benefit plan

B. (i) Items that will be reclassified to profit or loss (Foreign currency translation difference)

-Foreign currency translation difference

-Gain / (Loss) on cash flow hedge

(ii) Income tax relating to items that will be reclassified to profit or loss

-Foreign currency translation difference

-Gain / (Loss) on cash flow hedge

1.14

4.87

(0.10)

6.01

0.34

1.38

0.71

(1.82)

(2.04)

(1.11)

(2.36)

(7.22)

(0.69)

(0.53)

(1.13)

Total of Other Comprehensive Income / (Loss)

1.85

3.05

(z.s3)

4.90

(2.ss)

(6.97)

XII Total Comprehensive Income/(loss) for the period (x•xij

(10.04)

(7.42)

21.80

(17.46)

24.15

130.55

XIII Paid-up equity share capital (Face value of Z 2/- per share)

14.08

XIV Other Equity (Reserves excluding revaluation reserve)

2,421.81

XV Earnings per equity share (Face value of Z 2/- per share) (not annualized)

Basic
Diluted

(1.69)

(1.49)

3.50

3.49

(3.18)

3.79

3.78

19.53

19.47

UNICHEM LABORATORIES LIMITED Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India. Tel: +91(22)66474100. Website: https://www.unichemIabs.com. CIN: L99999MH 1962PLC012451
Statement of Consolidated Assets and Liabilities ' Crores
Particulars	As at 30th September, 2025	As at 31st March, 2025
I. ASSETS Non-current assets Property, plant and equipment Right-of-use assets Capital work-in-progress Goodwill Other intangible assets Financial assets Investments Loans Other financial assets Deferred tax assets (net) Other non-current assets Current assets Inventories Financial Assets Investments Trade receivables Cash and bank balances Cash & cash equivalents Other bank balances Loans Other financial assets Other current assets Non-Current Assets held for sale	Unaudited	Audited
	1,163.72 65.96 78.88 1.55 15.04 0.02 0.11 8.79 26.66 164.08	1,211.01 68.31 30.67 1.55 18.70 0.02 0.14 8.27 25.78 167.00
	1,524.81	1,531.45
	977.90 777.86 178.03 15.44 0.06 0.27 76.40	988.74 778.81 89.58 28.05 0.06 4.83 139.40
	2,025.96	2,029.47
	5.45	8.48
TOTAL ASSETS	3,556.22	3,569.40
II. EQUITY AND LIABILITIES Equity Equity share capital Other equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities Provisions Current tax liabilities (net) Non-Current Liabilities held for sale	14.08 2,420.76	14.08 2,436.51
	2,434.84	2,450.59
	43.29 23.84 37.23 0.42	60.81 25.19 37.86 0.64
	104.78	124.50
	430.22 4.61 18.37 300.05 45.39 36.30 181.20 0.46	369.16 4.61 7.67 394.88 50.68 22.99 137.64 4.34
	1,016.60	991.97
		2.34
TOTAL EQUITY AND LIABILITIES	3,556.22	3,569.40

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: https://www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Consolidated Cash Flows

T Grores

Particulars

Six months ended 30th September, 2025 (Unaudited)

Six months ended 30th September, 2024 (Unaudited)

A.Cash Flow from Operating Activities

Net Profit / (Loss) before tax Adjustments:

Depreciation / amortisation

Loss / (profit) on sale / discard of property, plant and equipment (net) * lmpairmement loss on property, plant and equipment

Unrealised exchange difference (gain) / loss (net) Gain on sale of subsidiary

Rent income * Finance cost

Provision for doubtful debts, loans, advances & deposits (net) Share-based payment to employees

Fair value (gain)/loss on investments (net) Interest income

Sundry balance written off / (written back) Provision for European commission fine Dividend income *

Operating Profit / (Loss) before Working Capital changes

Working Capital Adjustments:

Trade receivables & other assets Inventories

Trade payables & other liabilities

Cash generated from / (used in) operations Direct taxes refund received / (payment made)

Net Cash Flow from / (used in) Operating Activities [A]

(19.84)

63.26

0.16

3.12

0.69

(1.99)

(0.03)

14.78

(0.43)

0.50

(0.69)

(3.26)

58.26

34.94

64.33

(0.00)

5.54

(0.00)

8.82

0.61

1.02

(0.62)

(1.18)

(1.28)

(0.00)

77.23

112.17

12.81

(114.02)

45.29

(55.92)

56.26

(12.38)

44.23

10.84

(68.24)

134.37

114.53

(13.17)

101.36

(1.92)

99.44

43.88

B. Cash Flow from Investing Activities

Purchase of property, plant & equipment including capital work-in-progress Proceeds from sale of property, plant and equipment *

Proceeds from sale of investment in subsidiary Sale / (purchase) of current investment (net)

Rent received *

(Increase) / decrease in escrow bank accounts & fixed deposits Interest received

Dividend received *

Net Cash Flow from / (used in) Investing Activities [B]

(58.61)

0.00

4.00

0.03

12.61

4.38

(42.57)

0.29

1.34

0.00

(6.83)

1.02

0.00

(37.59)

(46.75)

C. Cash Flow from Financing Activities

Increase / (decrease) in working capital borrowings (net) Payments of lease liabilities

Repayments of term loan to bank Finance cost paid

Dividend paid (transferred to Investor Education and Protection Fund)

Net Cash Flow from / (used in) Financing Activities [C]

54.51

(3.09)

(12.84)

(12.36)

(0.31)

61.71

(2.40)

(12.83)

(8.29)

(0.32)

25.91

37.87

Net (Decrease) / Increase in Cash and Cash Equivalents [A+B+C]

Cash and Cash Equivalents at the beginning of the year

Effect of fair value gain / (loss) on liquid mutual funds

Cash and Cash Equivalents at the end of the year

87.76

89.58

0.69

178.03

35.00

154.75

0.62

190.37

* Amount less than s 0.5 lakhs

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: https://www.unichemIabs.com. CIN: L99999MH1962PLC012451

Notes:

The above unaudited consolidated financial results ("the Statement") for the quarter and half year ended 30th September, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2025. The statutory auditors have expressed an unmodified audit conclusion on these consolidated financial results for the quarter and half year ended 30th September, 2025.
The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.
Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.

In respect of the Company, deferred tax asset was recognised on the amount of tax loss, unabsorbed tax depreciation and other temporary differences upto the extent of deferred tax liability.

In respect of a subsidiary, deferred tax assets (net) are recognised as per applicable tax laws.

5 Exceptional Items comprise of the following:

T Crores

Particulars

Quarter ended

Half year ended

30.09.2025

30.06.2025

30.09.2024

30.09.2025

30.09.2024

Interest on European commission fine (refer note 8 below)

58.26

Total Exceptional Items - expenses / (income)

58.26

During the year ended 31st March, 2025, the Company and its wholly owned subsidiary "Unichem Pharmaceutical (USA), Inc." had entered into an agreement with Bayshore Pharmaceuticals LLC, USA ("Bayshore USA") (wholly owned step-down subsidiary of Ipca Laboratories Limited, Company's holding company) for purchase all of rights, title and interest in the product approvals and all goodwill associated with nine (9) ANDAs owned by Bayshore USA and purchase of USA generics formulations marketing/distribution business of Bayshore USA as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business.
Consequently, in accordance with Appendix C of Ind AS 103 'Business Combinations', the Company has restated the reported results of previous period (quarter and half year ended 30th September, 2024) to indude Bayshore USA transactions from the date of common control of Ipca Laboratories Limited. Further, these restated comparatives and results upto the date of agreement are based on the management certified figures.
Effective from 30th April, 2025 Unichem Laboratories Ireland, has ceased to be subsidiary of the Company. For the purpose of consolidation, figures of the subsidiary have been considered upto the aforesaid date and net gain of 7 1.99 crores have been recognised in the half year ended 30th September, 2025 under other income.
The Company and its subsidiary Niche Generics Ltd. ("Niche") has received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same is fully settled by the Company on 28th October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest is recorded in quarter and half year ended 30th September 2025 under exceptional items as reported in note 5 above.

By Order of the Board

SIGNED FOR IDENTIFICATION For Unichem Laboratories Limited

BHAVIN "' "°!! "•" ^ Pabitrakumar Date:

SURENDRA Kalipada 2025.11.11

KAPADIA Date: 2025.11.11 Bhattacharyya 12:16:10 +05'30'

12:29:20 +05'30'

N. A. SHAH ASSOCIATES LLP Pabitrakumar Kalipada Bhattacharyya

Place: Indore INDORE Managing Director

Date: 11th November, 2025 DIN: 07131152

N. A SHAH ASSOCIAES LLP

Charcerad Accountants

Independent Auditor's Review Report on Quarterly and Half yearly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Requlation 33 of the SEBI (Listinq Obliqations and Disclosure Requirements) Requlations, 2015, as amended

The Board of Directors Unichem Laboratories Limited

We have reviewed the accompanying statement of consolidated unaudited financial results of Unichem Laboratories Limited ("the Holding Company"), comprising its subsidiaries (the Holding and its subsidiaries collectively referred to as "the Group") for the quarter and half year ended 30th September 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
Management's responsibility
The Statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Further, the comparative figures for the quarter and half year ended 30th September 2024 are restated and the same are based on the Management certified accounts as disclosed in note 6 of the Statement.
Auditor's responsibility
Our responsibility is to issue a report on this Statement based on our review.
We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.
N. A. Shah Associates LLP is registered with limited liabililty having LLP identification No. AAG-79O9 Regd. Dff.: B 21-25, Paragon Centre, Pandurang Budhkar Marg, Worli, Mumbai 4OD O13.
Tel.: 91-E2-4O733DOO • Fax : 91-ZE-4O733O9O • E-mail : infoonashah.com

Independent Auditor's Review Report on Quarterly and Half yearly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)
These consolidated unaudited financial results include results of the following subsidiaries:
1. Niche Generics Limited, United Kingdom
2. Unichem Pharmaceuticals (USA), Inc., USA
3. Unichem Laboratories Limited, Ireland (upto 30th April 2025)
4. Unichem SA (Pty) Limited, South Africa
5. Unichem Farmaceutica Do Brasil Ltda, Brazil
6. Unichem (China) Pvt. Ltd.
  Basis for conclusion
Based on our review conducted and procedures performed as stated in above auditor's responsibility paragraph and based on the consideration of the review reports of the subsidiaries reviewed by another auditor and Management certified accounts furnished to us, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Other matters
We did not review the interim financial statements of the subsidiary at USA, whose interim financial statements reflect total assets of Rs. 1,051.10 crores as at 30th September 2025, total revenue (including other income) of Rs. 354.32 crores and Rs. 693.80 crores, total net profit after tax and total comprehensive income of Rs. 3.21 crores and Rs. 6.26 crores for the quarter and half year ended 30th September 2025 respectively and net cash inflow/ (outflow) of Rs. (11.49) crores for the half year ended 30th September 2025 as considered in the unaudited consolidated financial results. This financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and our report in terms of the Listing Regulations (as amended), in so far as it relates to aforesaid subsidiary located outside India is based on the report of other auditor and the procedures performed by us as stated in paragraph 3 above.
We also did not review the interim financial information of other subsidiaries as mentioned in paragraph 4 above, whose interim financial statements reflect total assets of Rs. 116.30 crores as at 30th September 2025, total revenue (including other income) of Rs. 56.70 crores and Rs. 111.49 crores, total net profit / (loss) after tax and total comprehensive income of Rs. (16.68) crores and Rs. (21.57) crores for the quarter and half year ended 30th September 2025 respectively and net cash inflow/ (outflow) of Rs. (2.32) crores for the half year ended 30th September 2025, as considered in the unaudited consolidated financial results. These financial information are not subject to limited review by their auditors and have been furnished to us by the Management and our conclusion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is solely based on the information provided by the Management. According to the information and explanations given to us by the Management, these financial information are not material to the Group.

Independent Auditor's Review Report on Quarterly and Half yearly Consolidated Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (continued)
In case of associate, Synchron Research Services Pvt. Ltd., the carrying value of investment had been fully impaired. Further, financial information of associate is not available for the half year ended 30th September 2025. In view of the above and in our opinion and according to the information and explanations given to us by the Management, this financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of the matters stated in paragraph 6, 7 and 8 above.

For N. A. Shah Associates LLP Chartered Accountants

Firm's Registration No.: 116560W/ W100149

BHAVIN Digitally signed by BHAVIN

SURENDRA KAPADIA

Bhavin Kapadia Partner

SURENDRA KAPADIA Date: 2025.11.11 12:27:10

Membership No.: 118991

UDIN: 25118991BMJHXM1098

Place: Indore

Date: 11th November 2025

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: https://www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2025

7 Crores

Particulars

Quarter ended

Half year ended

Year ended

30.09.2025

30.06.2025

30.09.2024

30.09.2025

30.09.2024

31.03.2025

Unaudited

Audited

I Revenue from operations

11 Other income

356.90

21.40

384.25

4.25

436.88

7.08

741.15

25.65

826.63

15.85

1,735.70

40.83

Ill Total income (I+II)

378.30

388.50

443.96

766.80

842.48

1,776.53

IV EXPENSES

Cost of materials consumed

165.31

203.88

215.64

369.19

415.96

829.77

Purchase of stock-in-trade

0.47

0.12

0.21

0.59

0.49

0.85

Changes in inventories of stock-in-trade, finished goods and work-

in-progress

6.91

(22.08)

(12.68)

(15.17)

(38.32)

(33.33)

Employee benefits expense

72.88

72.86

71.92

145.74

144.39

287.51

Finance costs

3.68

1.93

1.82

5.61

3.20

7.62

Depreciation and amortization expenses

30.11

29.93

26.39

60.04

52.49

108.41

Other expenses

103.63

103.73

97.29

207.36

199.42

397.02

Total expenses (IV)

382.99

390.37

400.59

773.36

777.63

1,597.85

V Profit / (Loss) before exceptional items and tax (III-IV)

Exceptional items - expenses/(income) (Refer note 4)

(4.69)

33.14

(1.87)

43.37

(6.56)

33.14

64.85

178.68

(4.00)

VII Profit / (Loss) before tax (V-VI)

(37.83)

(1.87)

43.37

(39.70)

64.85

182.68

VIII Tax expense

(1) Current tax

(2) Deferred tax charge / (credit)

2.10

(0.46)

1.64

19.72

(3) Short / (excess) provision for tax (earlier years)

0.44

2.10

(0.02)

2.08

19.72

IX Profit / (Loss) for the period after tax (VII-VIII)

(39.93)

(1.85)

43.37

(41.78)

64.85

162.96

X Other Comprehensive Income / (Loss)

A. (i) Items that will not be reclassified subsequently to profit or loss

- Remeasurement of the net defined benefit plan

(ii) Income tax (expense) / credit relating to items that will not

1.14

4.87

(0.11)

6.01

0.34

1.38

be reclassified to profit or loss

- Remeasurement of the net defined benefit plan

B. (i) Items that will be reclassified to profit or loss

- Gain/ (Loss) on cash flow hedge

(ii) Income tax relating to items that will be reclassified to profit or loss

- Gain/ (Loss) on cash flow hedge

(0.32)

(1.19)

(0.69)

(1.51)

(0.53)

(0.15)

(1.13)

Total of Other Comprehensive Income / (Loss)

0.82

3.68

(0.80)

4.50

(0.19)

0.10

Xl Total Comprehensive Income/(loss) for the period (IX+X)

(39.11)

1.83

42.57

(37.28)

64.66

163.06

XII Paid-up equity share capital (Face value of Z 2/- per share)

14.08

XIII Other Equity (Reserves excluding revaluation reserve)

2,430.97

XIV Earnings per equity share (Face value of Z 2/- per share) (not annualized)

Basic
Diluted

(5.67)

(0.26)

6.16

(5.93)

9.21

23.15

(5.67)

(0.26)

6.15

(5.93)

9.19

23.08

UNICHEM LABORATORIES LIMITED Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India. Tel: +91(22)66474100. Website: https://www.unichemIabs.com. CIN: L99999MH1962PLC012451
Statement of Standalone Assets and Liabilities 7Crores
Particulars	As at 30th September, 2025	As at 31st March, 2025
I. ASSETS Non-current assets Property, plant and equipment Right-of-use assets Capital work-in-progress Other Intangible assets Financial assets Investments Loans Other financial assets Other non-current assets Current assets Inventories Financial assets Investments Trade receivables Cash and bank balances Cash & cash equivalents Other bank balances Loans Other financial assets Other current assets Non-Current Assets held for sale	Unaudited	Audited
	1,161.21 49.79 79.25 15.04 47.17 35.63 6.79 162.88	1,204.76 51.23 31.03 18.70 45.62 34.32 6.34 141.35
	1,557.76	1,533.35
	605.29 651.17 160.98 15.44 8.94 0.27 65.85	584.06 748.14 60.58 28.05 8.61 4.83 132.07
	1,507.94	1,566.34
	5.45	9.52
TOTAL ASSETS	3,071.15	3,109.21
II. EQUITY AND LIABILITIES Equity Equity share capital Other equity Liabilities Non-current liabilities Financial liabilities Borrowings Lease liabilities Provisions Deferred tax liabilities (net) Other non-current liabilities Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises Other financial liabilities Other current liabilities Provisions	14.08 2,408.89	14.08 2,445.67
	2,422.97	2,459.75
	43.29 10.26 37.23 23.03 0.42	60.81 10.75 37.86 19.87 0.64
	114.23	129.93
	35.60 0.94 18.37 223.92 44.20 29.72 181.20	50.24 0.90 7.67 253.98 48.84 20.26 137.64
	533.95	519.53

TOTAL EQUITY AND LIABILITIES	3,071.15	3,109.21

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: https://www.unichemlabs.com. CIN: L99999MH1962PLC012451

Statement of Standalone Cash Flows

€Crores

Particulars

Six months ended

30th September, 2025 (Unaudited)

Six months ended

30th September, 2024 (Unaudited)

ACash Flow from Operating Activities

Net Profit / (Loss) before tax Adjustments:

Depreciation / amortisation

Loss / (profit) on sale / discard of property, plant and equipment (net)

Unrealised exchange difference (gain) / loss (net) Rent income *

Guarantee commission income Finance cost

Provision for doubtful debts, loans, advances & deposits (net) Fair value (gain)/loss on investments (net)

Interest income

Sundry balance written off / (written back) Provision for European commission fine

Operating Profit / (Loss) before Working Capital changes

Working Capital Adjustments:

Trade receivables & other assets Inventories

Trade payables & other liabilities

Cash generated from / (used in) operations

Direct taxes refund received / (payment made)

Net Cash Flow from / (used in) Operating Activities [A]

(39.70)

60.04

0.17

2.99

(0.03)

(1.27)

5.61

(0.43)

(0.69)

(4.30)

33.14

95.23

55.53

143.69

(21.23)

(5.53)

116.93

172.46

3.90

64.85

52.49

1.91

(0.14)

3.20

0.61

(0.62)

(0.73)

(1.28)

55.44

120.29

(37.50)

(58.46)

48.30

(47.66)

72.63

(0.08)

176.36

72.55

B. Cash Flow from Investing Activities

Purchase of property, ant & equipment including capital work-in-progress Proceeds from sale of property, ant and equipment *

Investments made

- in subsidiaries (at cost)

Guarantee commission income realised Proceeds from sale of investment in subsidiary Sale / (purchase) of current investment (net)

Rent received *

(Increase) / decrease in escrow bank accounts & fixed deposits Interest received

Dividend received *

Net Cash Flow from / (used in) Investing Activities [B]

(59.20)

0.00

(1.05)

0.06

4.00

0.03

12.61

5.42

(36.68)

0.91

(0.84)

0.14

1.34

0.00

(6.83)

0.57

0.00

(38.13)

(41.39)

C. Cash Flow from Financing Activities

Increase / (decrease) in working capital borrowings (net) Repayments of term loan to bank

Payments of lease liabilities Finance cost paid

Dividend paid (transferred to Investor Education and Protection Fund)

Net Cash Flow from / (used in) Financing Activities [C]

(21.19)

(12.84)

(0.97)

(3.22)

(0.30)

20.86

(12.83)

(0.26)

(2.73)

(0.32)

(38.52)

4.72

Net (Decrease) / Increase in Cash and Cash Equivalents [A+B+C]

Cash and Cash Equivalents at the beginning of the year Effect of fair value gain / (loss) on liquid mutual funds

Cash and Cash Equivalents at the end of the year

99.71

60.58

0.69

160.98

35.88

125.65

0.62

162.15

* Amount less than ¥ 0.5 lakhs

UNICHEM LABORATORIES LIMITED

Regd. Office: 47, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, Maharashtra, India.

Tel: +91(22)66474100. Website: https://www.unichemIabs.com. CIN: L99999MH1962PLC012451

Notes:

The above unaudited standalone financial results ("the Statement") for the quarter and half year ended 30th September, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2025. The statutory auditors have expressed an unmodified audit confusion on these standalone financial results for the quarter and half year ended 30th September, 2025.
The above Statement has been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI") and the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.
Operating Segment: The Company has a single reportable segment i.e. 'Pharmaceuticals'.

Exceptional Items comprise of the following:

7 Crores

Particulars

Quarter ended

Half year ended

Year ended

30.09.2025

30.06.2025

30.09.2024

30.09.2025

30.09.2024

31.03.2025

Reversal of Impairment of Investment in subsidiary "Unichem Laboratories Limited -

Ireland" (refer note 5 below)

(4.00)

Interest on European commission fine (refer note 6 below)

58.26

Reversal of provision for European commission fine (Net) (refer note 6 below)

(25.12)

Total Exceptional Items - expenses / (income)

33.14

(4.gg)

The Company has transferred its 100% stake in its wholly owned subsidiary "Unichem Laboratories Limited, Ireland" (Unichem Ireland), to Company's holding company, "Ipca Laboratories Limited" which is concluded on 30th April, 2025. During the quarter and year ended 31st March, 2025 impairment provision was reversed to the extent of 7 4.00 crores, i.e. the agreed consideration for the aforesaid transfer.

The Company and its subsidiary Niche Generics Ltd. ("Niche") has received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same is fully settled by the Company on 28th October 2025 after adjusting the payments of Euro

2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31st March 2024 and the balance amount representing the interest is recorded in quarter and half year ended 30th September 2025 under exceptional items as reported in note 4 above.

7 During the quarter ended 30th September 2025, the Company has invested USD 1,20,000 (equivalent to Rs. 1.05 crores) towards redeemable preference shares in its wholly owned subsidiary - "Unichem (China) Pvt Ltd."

By Order of the Board

SIGNED FOR IDENTIFICATION For Unichem Laboratories Limited

BHAVIN "'°"°"°"° ^ Pabitrakumar Date: 2025.J 1.J 1

SURENDRA Kalipada 12:16:41 +05'30'

Bhattacharyya

N. A. SHAH ASSOCIATES LLP Pabitrakumar Kalipada Bhattacharyya Place: Indore INDORE Managing Director

Date: 11th November, 2025 DIN: 07131152

N. A EHAH ASEOCIAES LLP

Eharcerad Accountants

Independent Auditor's Review Report on Quarterly and Half yearly Standalone Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Requlation 33 of the SEBI (Listinq Obliqations and Disclosure Requirements) Requlations, 2015, as amended

The Board of Directors

Unichem Laboratories Limited

We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of Unichem Laboratories Limited ("the Company") for the quarter and half year ended 30th September, 2025, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
Management's responsibility
The Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
Auditor's responsibility
Our responsibility is to issue a report on this Statement based on our review.
We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
N. A. Shah Associates LLP is registered with limited liabililty having LLP identification No. AAG-79O9 Regd. Off.: B 21-25, Paragon Centre, Pandurang Budhkar Marg. Worli, Mumbai 4OO O13.
Tel.: 91-22-4O733OOO • Fax : 91-22-4O733O9O • E-mail : [email protected]
N. A SHAH ASSOCIAES LLP
Chartered Accountants
Independent Auditor's Review Report on Quarterly and Half yearly Standalone Unaudited Financial Results of Unichem Laboratories Limited pursuant to the Requlation 33 of the SEBI (Listinq Obliqations and Disclosure Requirements)Requlations, 2015, as amended (continued)
Conclusion
Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards i.e. 'Ind AS' prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. A. Shah Associates LLP Chartered Accountants

Firm's Registration No.: 116560W / W100149

BHAVIN

Digitally signed by BHAVIN SURENDRA

SURENDRA KAPADIA

KAPADIA

Date: 2025.11.11 1 2:26:11

+05'30'

Bhavin Kapadia Partner

Membership No.: 118991 UDIN: 25118991BMJHXL5641

Place: Indore

Date: 11th November 2025